This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
Sun Pharma gets 8 observations from USFDA for Halol facility
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Subscribe To Our Newsletter & Stay Updated
